A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)
Sponsor: Alkermes, Inc.
Listed as NCT06843590, this PHASE2 trial focuses on Idiopathic Hypersomnia and remains actively recruiting participants. Sponsored by Alkermes, Inc., it has been updated 7 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alkermes, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alken, Belgium , Atlanta, United States , Austin, United States , Barcelona, Spain , Bedford Park, Australia , Bologna, Italy , Bordeaux, France , Brandon, United States , Canton, United States , Cincinnati, United States and 37 more locations